Key result
TRAP-6 inducible aggregation correlated with ADP inducible aggregation (r=0.33 to 0.72; p<0.001), but its use as a positive control for platelet reactivity has major limitations.
Why the study?
Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel in patients on dual antiplatelet therapy?
Cross-Sectional (n=200)
Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel in patients on dual antiplatelet therapy?
TRAP-6 has major limitations as a positive control for assessing residual platelet reactivity to ADP in patients on clopidogrel, and results must be interpreted cautiously.
Answers are grounded in this paper and cite their sources.
TRAP-6 use as positive control warrants caution in clopidogrel-treated patients; Level 4 data leaves optimal platelet reactivity controls unresolved.
Adenosine 5′-diphosphate (ADP) inducible aggregation is used to assess platelet response to thienopyridines. Thrombin receptor-activating peptide-6 (TRAP-6) inducible aggregation may serve as a positive control because it acts via the thrombin receptor protease-activating receptor-1, which is not blocked by thienopyridines. We therefore investigated if TRAP-6 is suitable as a positive control when assessing residual platelet reactivity to ADP. Platelet response to clopidogrel was assessed in 200 patients on dual antiplatelet therapy using ADP inducible platelet aggregation by light transmission aggregometry (LTA), multiple electrode aggregometry (MEA), and the shear-dependent Impact-R. Test specificities were monitored by TRAP-6 inducible platelet aggregation. The aggregation-independent vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay served for comparisons. ADP inducible aggregation was correlated to that by TRAP-6 (r = 0.33 to 0.72; p < 0.001 for all assays). A linear correlation was seen within MEA (r = 0.72). LTA TRAP-6 correlated weakly with the VASP assay (r = 0.19; p = 0.01), while there were no correlations of TRAP-6 responses by MEA or the Impact-R with the VASP assay (r = 0.03 and −0.09; p > 0.05). In all three assays, differences between ADP and TRAP-6 inducible aggregation varied considerably. Within MEA, TRAP-6 inducible aggregation was almost always stronger than ADP inducible aggregation, while within LTA and the Impact-R, weak responses to ADP were associated with both, weak and strong responses to TRAP-6. In conclusion, the application of TRAP-6 as a positive control for platelet reactivity has major limitations and results need to be cautiously interpreted on an individual basis.
No takes yet. Share an insight, caveat, or question.
Gremmel et al. (2010) conducted a cross-sectional in Patients on dual antiplatelet therapy (n=200). TRAP-6 inducible platelet aggregation vs. ADP inducible aggregation was evaluated on Correlation between ADP and TRAP-6 inducible aggregation (r = 0.33 to 0.72, p=<0.001). TRAP-6 inducible aggregation correlated with ADP inducible aggregation (r=0.33 to 0.72; p<0.001), but its use as a positive control for platelet reactivity has major limitations.
Synapse has enriched 10 related papers. Consider them for comparative context: